Benzonatate and Klor-con m20 drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Benzonatate (benzonatate) and Klor-con m20 (potassium chloride). Common drug interactions include body height decreased among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Benzonatate and Klor-con m20. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Benzonatate?

Benzonatate has active ingredients of benzonatate. It is often used in cough. eHealthMe is studying from 17,274 Benzonatate users. Check the latest studies of Benzonatate.

What is Klor-con m20?

Klor-con m20 has active ingredients of potassium chloride. It is often used in hypokalemia. eHealthMe is studying from 2,411 Klor-con m20 users. Check the latest studies of Klor-con m20.

On Jul, 08, 2026

35 people who take Benzonatate and Klor-con m20 together, and have interactions are studied.

Benzonatate and Klor-con m20 drug interactions.

What are the common drug interactions of Benzonatate and Klor-Con M20, by gender? *:

female:

Body height decreased
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Dyspepsia (indigestion)
Fatigue (feeling of tiredness)
Fear
Gastric cancer (stomach cancer)
Rash
Sleep disorder
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Viral uveitis (inflammation at any point of the uveal track)

male:

Diarrhoea
General physical health deterioration (weak health status)
Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
Deafness
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hypoacusis (loss of hearing)
Injection site bruising
Loss of consciousness
Nasopharyngitis (inflammation of the nasopharynx)
Plasma cell myeloma (cancer that begins in plasma cells)

What are the common drug interactions of Benzonatate and Klor-Con M20, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Dyspepsia (indigestion)
Fear
Gastric cancer (stomach cancer)
Sleep disorder
Weight decreased
Chronic kidney disease
Neutropenia (an abnormally low number of neutrophils)
Pneumonia

60+:

Body height decreased
Diarrhoea
Depression
Drug ineffective
Dysgeusia (disorder of the sense of taste)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hypoacusis (loss of hearing)
Hypotension (abnormally low blood pressure)
Loss of consciousness
Nasopharyngitis (inflammation of the nasopharynx)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 13 people, 37.14%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 11.43%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 8.57%
Diabetes: 3 people, 8.57%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 3 people, 8.57%
Dyspnea (difficult or laboured breathing): 3 people, 8.57%
Dry Eyes (lack of adequate tears): 3 people, 8.57%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 3 people, 8.57%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 8.57%
Diarrhea: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Benzonatate and Klor-con m20?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously